Drugs / Seletracetam
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00152503 | Aug 2005 → May 2006 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00152451 | May 2005 → May 2006 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00422110 | May 2008 → ? | focal epilepsy | UCB Pharma | Withdrawn | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00175851 | May 2008 → ? | epilepsy | UCB Pharma | Withdrawn | No outcome recorded |
| Phase 3 | NCT00175864 | Feb 2006 → ? | epilepsy | UCB Pharma | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seletracetam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00175851 ↗ |
| Known as | UCB44212 | “Seletracetam (ucb 44212)” NCT00152451 ↗3“Seletracetam (ucb 44212)” NCT00175864 ↗ “Seletracetam (ucb 44212)” NCT00175851 ↗ “Seletracetam (UCB44212)” NCT00152503 ↗ |
| Modality | Small molecule | — CHEMBL3918017 ↗ |
| Route | Oral | “Route of administration: oral administration” NCT00152451 ↗ |
| Target | SV2A | “Synaptic vesicle glycoprotein 2A modulator” CHEMBL3918017 ↗ |